Structure Therapeutics Inc.
GPCR
$54.51
-$0.19-0.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 73.81M | 70.98M | 61.55M | 57.56M | 56.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -100.00M | -100.00M | -100.00M | -- | -- |
| Total Operating Expenses | 268.06M | 219.88M | 186.81M | 247.61M | 219.66M |
| Operating Income | -268.06M | -219.88M | -186.81M | -247.61M | -219.66M |
| Income Before Tax | -214.13M | -169.73M | -140.69M | -210.20M | -178.49M |
| Income Tax Expenses | 702.00K | 607.00K | 515.00K | 481.00K | 465.00K |
| Earnings from Continuing Operations | -214.84 | -170.34 | -141.20 | -210.69 | -178.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -214.84M | -170.34M | -141.20M | -210.69M | -178.95M |
| EBIT | -268.06M | -219.88M | -186.81M | -247.61M | -219.66M |
| EBITDA | -265.79M | -217.89M | -185.13M | -246.40M | -218.55M |
| EPS Basic | -9.34 | -8.17 | -7.47 | -10.94 | -9.36 |
| Normalized Basic EPS | -1.91 | -1.67 | -1.53 | -2.14 | -1.81 |
| EPS Diluted | -9.34 | -8.17 | -7.47 | -10.94 | -9.36 |
| Normalized Diluted EPS | -1.91 | -1.67 | -1.53 | -2.14 | -1.81 |
| Average Basic Shares Outstanding | 266.98M | 251.87M | 236.78M | 230.69M | 229.41M |
| Average Diluted Shares Outstanding | 88.99M | 83.96M | 78.93M | 76.90M | 76.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |